Official Title
High Prevalence of Deep Venous Thrombosis in Non-severe COVID-19 Patients Hospitalized for a Neurovascular Pathology
Brief Summary

Severe SARS-CoV-2 infection, responsible of COVID-19, is accompanied by many venous thromboembolic events. Antithrombotic treatment is the cornerstone of management of many neurovascular diseases (NVDs) and the benefit-risk ratio is crucial to avoid hemorrhagic complications. Therefore, in non-severe COVID-19 patients affected by NVDs, the diagnostic of deep venous thrombosis (DVT) is challenging. Using bedside Doppler ultrasonography (DUS) of lower limbs, this study investigated the rates of DVT in these patients in stroke unit.

Completed
Deep Venous Thrombosis
Eligibility Criteria

- Inclusion criteria:

- Age>18 years

- COVID-19 confirmed with RT-PCER and/or chest CT-scan

- Acute neurovascular disease defined as transient ischemic attack or acute
ischemic stroke or venous cerebral thrombosis or hemorrhagic stroke.

- Exclusion criteria:

- age<18

- Other neurovascular diseases

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
France
Locations

Service Unité Neurovasculaire
Strasbourg, France

University Hospital, Strasbourg, France
NCT Number
Keywords
non-severe COVID-19
neurovascular diseases
Doppler ultrasound
Deep Venous Thrombosis
Covid-19
SARS-CoV-2
MeSH Terms
COVID-19
Thrombosis
Venous Thrombosis